ライフサイエンスコーパス: systolic

1 The placebo-corrected reduction in systolic 24-h blood pressure with the quadpill was 19 mm

2 odium excretion was directly associated with systolic (4.58 mm Hg; 95% confidence interval [CI], 2.64

3 sessed using the following parameters: early systolic (_ES); slope of -volume relationship during sys

4 e primary outcome was placebo-corrected 24-h systolic ambulatory blood pressure reduction after 4 wee

5 tihypertensive medications while maintaining systolic and diastolic blood pressure <140 mm Hg and 90

6 ndations for the definition of hypertension, systolic and diastolic blood pressure (BP) thresholds fo

7 rs (SD 11) and mean baseline office and 24-h systolic and diastolic blood pressure levels were 154 (1

8 (GERA) cohort individuals provided 1,342,814 systolic and diastolic blood pressure measurements for a

9 ge range, the average rate of change in both systolic and diastolic blood pressure was greater among

10 mm Hg (14-29/7-16) at 6 months (p<0.0001 for systolic and diastolic blood pressure).

11 s and others in biological (body-mass index, systolic and diastolic blood pressure, and handgrip stre

12 ) cholesterol, triglycerides, fat mass (FM), systolic and diastolic blood pressure, fasting insulin a

13 ts across eight cardiometabolic traits (BMI, systolic and diastolic blood pressure, LDL cholesterol,

14 ositively associated with self-reported IHD, systolic and diastolic blood pressure, low-density lipop

15 and identified several cis-eGenes (ALDH2 for systolic and diastolic blood pressure, MCM6 and DARS for

16 difference in the average rate of change in systolic and diastolic blood pressure, respectively, whe

17 mference, triglycerides, HDL-c, glucose, and systolic and diastolic blood pressure.

18 ratio of TC to HDL cholesterol (TC:HDL), and systolic and diastolic blood pressures (SBP and DBP, res

19 (n = 11,767), we found significantly higher systolic and diastolic blood pressures among those who e

20 strongly associated with BP (P<10(-320)) for systolic and diastolic BP and CVD events regardless of t

21 e coprimary outcomes were the differences in systolic and diastolic BP changes from baseline to the e

22 lysis of the cross-sectional associations of systolic and diastolic BP with blood-derived genome-wide

23 and 2.0% of the interindividual variation in systolic and diastolic BP, respectively.

24 Ca(2+) ATPase as the principal regulators of systolic and diastolic Ca(2+) , respectively.

25 TPase (SERCA) as the principal regulators of systolic and diastolic Ca(2+) , respectively.

26 ss hypertrophy, smaller left atria, and less systolic and diastolic dysfunction than FG+ probands wit

27 Echocardiograms were performed to assess systolic and diastolic function from 14 weeks of age.

28 h LV concentric remodeling and impairment of systolic and diastolic function parameters, whereas an i

29 Left ventricular (LV) morphology and systolic and diastolic function were evaluated with card

30 stitial collagen deposition and a decline in systolic and diastolic function were present only in WT

31 aits of left ventricular (LV) structure, and systolic and diastolic function.

32 ed with LV eccentric remodeling and improved systolic and diastolic functional variables.

33 BK application in CHF rats increased cardiac systolic and diastolic volumes and further increased the

34 itude increased linearly with the diastolic, systolic and mean BP.

35 mm Hg (13-34/6-18) at 6 months (p=0.0003 for systolic and p=0.0001 diastolic blood pressure).

36 e adults with resistant hypertension (office systolic blood pressure >/=160 mm Hg despite taking at l

37 response syndrome criteria) and hypotension (systolic blood pressure </=90 mm Hg or mean arterial pre

38 eter blood withdrawal to achieve a sustained systolic blood pressure <10 mmHg, cardiac arrest.

39 gnificant between-group mean differences for systolic blood pressure (-1.26 mm Hg [95% CI, -1.77 to -

40 icantly lower adjusted time-weighted average systolic blood pressure (-17 mm Hg; 95% CI, -25 to -8; p

41 sium excretion was inversely associated with systolic blood pressure (-3.72 mm Hg; 95% CI, -6.01 to -

42 The correlation was low for systolic blood pressure (0.39; P<0.0001).

43 sion (OR = 1.6, 95% CI = 1.2-2.3), increased systolic blood pressure (1.2 per 20mmHg, 95% CI = 1.1-1.

44 ed in a factorial design to target levels of systolic blood pressure (130-149mmHg vs <130mmHg; open l

45 genes were associated with a 23 mm Hg higher systolic blood pressure (95% CI, 12-34; P=5.6*10(-5)) an

46 sly, an inverse association was observed for systolic blood pressure (hazard ratio=0.79 [95% CI: 0.68

47 R: 2.18; 95% CI: 1.58, 3.02), new-onset high systolic blood pressure (OR: 1.34; 95% CI: 1.05, 1.70),

48 compared with the HabDiet, resulted in lower systolic blood pressure (P-diet x time interaction = 0.0

49 history of cardiovascular disease and normal systolic blood pressure (SBP < 130 mmHg).

50 6.9% = 1.33, OR7-7.9% = 1.86, OR8%+ = 3.22), systolic blood pressure (SBP) (ORper 10mmHg+ = 1.19), an

51 e aimed to test the hypothesis that elevated systolic blood pressure (SBP) across its usual spectrum

52 were associated under an additive model with systolic blood pressure (SBP) and age at diagnosis of hy

53 ement of Aortic Transcatheter Valve) who had systolic blood pressure (SBP) and an echocardiogram obta

54 cemic index (GI) and glycemic load (GL) with systolic blood pressure (SBP) and diastolic blood pressu

55 rom baseline to the end of the trial in both systolic blood pressure (SBP) and diastolic blood pressu

56 mference (WC), waist-to-height ratio (WHtR), systolic blood pressure (SBP) and diastolic blood pressu

57 odium-DASH vs. high sodium-control diets) on systolic blood pressure (SBP) by baseline BP.

58 anol users and control subjects (P = 0.040); systolic blood pressure (SBP) did not differ (P = 0.86).

59 Recent guidelines recommend a systolic blood pressure (SBP) goal of less than 150 mm H

60 servational studies have shown that elevated systolic blood pressure (SBP) is associated with future

61 the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear.

62 chronic kidney disease (CKD) with intensive systolic blood pressure (SBP) lowering is unclear.

63 Patients with an office systolic blood pressure (SBP) of 150 mm Hg or greater an

64 vascular disease (ASCVD) risk to personalize systolic blood pressure (SBP) treatment goals is a topic

65 zed management strategy aimed at achieving a systolic blood pressure (SBP) within 10% of the referenc

66 The causal relationship between systolic blood pressure (SBP), calf electromyography (EM

67 ion of FR167653, p38 MAPK inhibitor, reduced systolic blood pressure (SBP), urinary albumin excretion

68 h interleukin-6 (Spearman r=0.33, P<0.0001), systolic blood pressure (Spearman r=0.28, P<0.0001), bod

69 1.4]; 22 trials, 2721 participants), diurnal systolic blood pressure (WMD, -2.4 points [95% CI, -3.9

70 re (hazard ratio=0.79 [95% CI: 0.68-0.92] at systolic blood pressure 160 vs 110 mm Hg) but not for di

71 % CI, -8.6 to -4.2; 6 studies; I2 = 51%) for systolic blood pressure and -4.0 mm Hg (95% CI, -5.6 to

72 ockers was associated with better control of systolic blood pressure and attenuation of decline in bo

73 ract surgery, PEX was associated with higher systolic blood pressure and more frequent ECG abnormalit

74 alysis to understand the indirect effects of systolic blood pressure and serum aldosterone on the rel

75 sity lipoprotein-cholesterol, triglycerides, systolic blood pressure and the incidence of the metabol

76 pressure, a slowdown in the increase of both systolic blood pressure and waist circumference, and a r

77 omparison with MESA, HealthLNK overestimated systolic blood pressure by 6.5 mm Hg (95% confidence int

78 Over 3 months, systolic blood pressure decreased, and estimated glomeru

79 t daytime and night-time with less effect on systolic blood pressure in CHF rats.

80 nsin-aldosterone system genes associate with systolic blood pressure individually in both sexes, indi

81 In the Systolic Blood Pressure Intervention Trial (SPRINT), adu

82 The previously published results of the Systolic Blood Pressure Intervention Trial showed that a

83 nd 19.5% (95% CI, 18.5-20.5) met the SPRINT (Systolic Blood Pressure Intervention Trial) eligibility

84 he primary end point considering the SPRINT (Systolic Blood Pressure Intervention Trial) target reach

85 no diabetes mellitus from the SPRINT trial (Systolic Blood Pressure Intervention Trial): 4086 random

86 this population, we defined hypertension as systolic blood pressure of at least 140 mm Hg, or diasto

87 er among those who were assigned to a target systolic blood pressure of less than 120 mm Hg (intensiv

88 ceived intensive treatment, which targeted a systolic blood pressure of less than 120 mm Hg, were sim

89 dividualized assessment, to achieve a target systolic blood pressure of less than 140 mm Hg to reduce

90 ransient ischemic attack to achieve a target systolic blood pressure of less than 140 mm Hg to reduce

91 ly at or above 150 mm Hg to achieve a target systolic blood pressure of less than 150 mm Hg to reduce

92 atment in adults aged 60 years or older with systolic blood pressure persistently at or above 150 mm

93 Higher systolic blood pressure showed an inverse association wi

94 poor neighborhoods was associated with lower systolic blood pressure than was consistent residence in

95 e analyses adjusting for age and sex, higher systolic blood pressure values were noted for the PEX gr

96 itional antihypertensive medication, and the systolic blood pressure was 14.8 mm Hg (95% confidence i

97 After 6 mmol of KNO3, systolic blood pressure was reduced by a maximum of 17.9

98 TR1) were individually associated with lower systolic blood pressure with significant (P<0.00076) eff

99 rdiometabolic risk factors: body mass index, systolic blood pressure, and fasting glucose level.

100 ng, rectal examination findings, heart rate, systolic blood pressure, and haemoglobin concentration s

101 rmediate outcomes of hemoglobin A1c, weight, systolic blood pressure, and heart rate; all-cause morta

102 seline in glycated hemoglobin level, weight, systolic blood pressure, and mean daily bolus dose of in

103 , injury severity score, Glascow Coma Scale, systolic blood pressure, base excess, platelet count, he

104 adjustment for age, sex, diabetes diagnosis, systolic blood pressure, BMI, smoking status, estimated

105 risk, management targeting an individualized systolic blood pressure, compared with standard manageme

106 BMI, systolic blood pressure, coronary artery disease and typ

107 or cognitive ability in youth), BMI, height, systolic blood pressure, coronary artery disease, and ty

108 educational attainment predicted lower BMI, systolic blood pressure, coronary artery disease, type 2

109 eristics following stratification, including systolic blood pressure, history of diabetes mellitus or

110 adjusting for age, race, body surface area, systolic blood pressure, history of hypertension, curren

111 SGLT2 inhibition caused marked decreases in systolic blood pressure, kidney weight/body weight ratio

112 ment for age, sex, heart rate, hypertension, systolic blood pressure, left ventricular ejection fract

113 lder, had longer hemodialysis vintage, lower systolic blood pressure, lower ultrafiltration rates, hi

114 14) with more than 1 million measurements of systolic blood pressure, total cholesterol, and high-den

115 Systolic blood pressure, waist circumference (WC), and f

116 intensive control versus standard control of systolic blood pressure.

117 which had shown individual association with systolic blood pressure.

118 pituitary-thyroid axes, as well as a rise in systolic blood pressure.

119 rtensive patients, which was correlated with systolic blood pressure.

120 ardiovascular disease who received intensive systolic blood-pressure control (target, <120 mm Hg) had

121 In this simulation study, intensive systolic blood-pressure control prevented cardiovascular

122 ned 9361 participants with hypertension to a systolic blood-pressure target of less than 120 mm Hg or

123 etes mellitus, intensive BP lowering (target systolic BP <120 mm Hg) compared with standard BP loweri

124 hypertensive patients, intensive BP control (systolic BP <140 mm Hg) decreased MACE, including cardio

125 ) compared with standard BP lowering (target systolic BP <140 mm Hg) resulted in lower rates of devel

126 women, black race, and 3 levels of baseline systolic BP (</=132 versus >132 to <145 versus >/=145 mm

127 an increase in the low frequency spectra of systolic BP (13.9 +/- 4.3% total power; P < 0.001), indi

128 in patients with ICH (<6 hours) and elevated systolic BP (150-220 mm Hg).

129 ociated with a 1.04-mm Hg decrement in adult systolic BP (95% confidence interval (CI): -2.14, 0.06)

130 ot total body overhydration, correlated with systolic BP (r=0.33, P=0.002).

131 regression models, each 1-mm Hg increment in systolic BP (SBP) was associated with 0.8% (95% confiden

132 Mayo Clinic, Rochester, MN, grouped by peak systolic BP achieved during the test.

133 d adolescents during the last 20 years, with systolic BP and BMI in boys above the reference.

134 confidence interval, 0.663-0.744) for clinic systolic BP and diastolic BP.

135 to percentiles from the 81.6th to 99.9th for systolic BP and from the 92.9th to 98.9th for diastolic

136 ice with Tmem27(Y/-) kidneys had the highest systolic BP and were the only group to exhibit glomerula

137 tervention period, but in the intensive arm, systolic BP decreased from 160 mmHg at baseline to 143 m

138 the standard arm, the 2-week moving average systolic BP did not change significantly during the inte

139 yle score) had 3.6, 3.5, and 3.6 mm Hg lower systolic BP in low, middle, and high genetic risk groups

140 e is a modest but significant improvement in systolic BP in randomized controlled trials of self-meas

141 2) systolic BP lowering to a target of <130 mm Hg may reduc

142 were available for association analysis with systolic BP or diastolic BP or pulse pressure.

143 versus -6.8/-3.5 mm Hg, respectively, Delta systolic BP P=3x10(-4), Delta diastolic BP P=5x10(-5)).

144 Systolic BP reduction from baseline to month 18 was 19.3

145 e and the increased low frequency spectra of systolic BP response were fully maintained despite RVLM

146 stolic BP target <140 mm Hg) with intensive (systolic BP target <120 mm Hg) BP treatment and data fro

147 Results of 2 trials comparing standard (systolic BP target <140 mm Hg) with intensive (systolic

148 At 6 months, the mean systolic BP was 123.2+/-13.2 mm Hg in the aggressive BP

149 trends were not consistent, for both sexes, systolic BP z-score was stable from 1999, decreased slig

150 Targeting a systolic BP<120 mm Hg, compared with <140 mm Hg, signifi

151 g., to -0.90 mm Hg (95% CI: -1.94, 0.14) for systolic BP).

152 ng treatment interactions with age, baseline systolic BP, and diastolic BP, and the SAE model had 8 v

153 served no significant difference in achieved systolic BP, AngII-treated APA-KO mice developed a signi

154 risk of CKD per 1-SD decrease in mean asleep systolic BP, independent of changes in mean clinic BP or

155 isk exposure between ages 6 and 24 years) of systolic BP, total-cholesterol, and smoking associated i

156 FBX had a modest systolic BP-lowering effect in T1D patients (112 +/- 10

157 age>/=75 years, body mass index, and higher systolic BP.

158 ydrochlorothiazide versus noncarriers (Delta systolic BP/Delta diastolic BP: -12.3/-8.2 versus -6.8/-

159 ism by which changes of the amplitude of the systolic Ca transient control diastolic [Ca(2+) ]i .

160 panied by a decrease of the amplitude of the systolic Ca transient, such that there was no change of

161 show that the ability to dynamically change systolic Ca(2+) , through changes in expression of key C

162 sm by which increased Ca buffering decreases systolic Ca(2+) in old atria.

163 ased Ca buffering can account for changes to systolic Ca(2+) in the old atria.

164 the aortic banding model, the sensitivity of systolic Ca(2+) to LCC density and diastolic Ca(2+) to S

165 This is accompanied by a decrease of systolic [Ca(2+) ]i such that the time-averaged [Ca(2+)

166 Impaired diastolic and systolic cardiac function was observed in IUGR offspring

167 ne learning of three-dimensional patterns of systolic cardiac motion.

168 All measures of systolic contractile function fell during HD and HDF, wi

169 olic peak (peak ); and diastolic uncoupling (systolic -diastolic at same volume) during early diastol

170 changes on electrocardiography; decreased LV systolic, diastolic diameter, or septal E' velocity; hig

171 The method yielded central systolic, diastolic, and pulse pressure bias and precisi

172 plained 2.9%, 2.5%, and 3.1% of variation in systolic, diastolic, and pulse pressure, respectively, i

173 -wide association study on long-term average systolic, diastolic, and pulse pressure.

174 eport genetic association of blood pressure (systolic, diastolic, pulse pressure) among UK Biobank pa

175 icipants, 40 to 79 years of age, with clinic systolic/diastolic BP <140/90 mm Hg, who completed ambul

176 mg/L reduction in sodium in drinking water, systolic/diastolic BP was lower on average by 0.95/0.57

177 tivation, ventricular arrhythmic burden, and systolic/diastolic dysfunction (all p < 0.05).

178 ed whether an internally scaled index of end-systolic dimension is incremental to well-validated prog

179 failure, and increased left ventricular end-systolic dimension zscore at diagnosis were independentl

180 Right ventricular (RV) end-systolic dimensions provide information on both size and

181 hat all LV parameters (LV end-diastolic and -systolic dimensions, ejection fraction, and fractional s

182 Left ventricular systolic dysfunction (LVSD) accounts for almost 25% of n

183 trial fibrillation (AF) and left ventricular systolic dysfunction (LVSD) frequently co-exist despite

184 ents with AMI without HF or left ventricular systolic dysfunction (LVSD).

185 ical Rate Control in Atrial Fibrillation and Systolic Dysfunction [CAMERA-MRI]; ACTRN12613000880741).

186 pendently associated with the development of systolic dysfunction among moderate-severe traumatic bra

187 trial and ventricular remodeling, along with systolic dysfunction and comparable intra-cardiac fibros

188 Left ventricular (LV) systolic dysfunction and moderate aortic stenosis (AS) a

189 Patients with concomitant moderate AS and LV systolic dysfunction are at high risk for clinical event

190 cal data of patients with moderate AS and LV systolic dysfunction between 2010 and 2015 from 4 large

191 Early systolic dysfunction can occur in previously healthy pat

192 valve area between 1.0 and 1.5 cm(2) and LV systolic dysfunction defined as LV ejection fraction <50

193 dinal course, and admission risk factors for systolic dysfunction in patients with moderate-severe tr

194 In chronic Chagas disease, RV systolic dysfunction is more commonly associated with le

195 All patients with early systolic dysfunction recovered in 1 week.

196 of future arrhythmic events in patients with systolic dysfunction using the gold standard of cardiova

197 ssessed by transthoracic echocardiogram, and systolic dysfunction was defined as fractional shortenin

198 RV systolic dysfunction was defined as reduced RV ejection

199 t ventricular ejection fraction, isolated RV systolic dysfunction was found in 7 (4.4%) patients, 2 o

200 osis was present in 55 patients (72%) and LV systolic dysfunction was identified in 13 patients (24%)

201 on was used to verify the relationship of RV systolic dysfunction with age, sex, functional class, us

202 0%) mild traumatic brain injury patients had systolic dysfunction within the first day after injury (

203 re commonly associated with left ventricular systolic dysfunction, although isolated and early RV dys

204 tion, including arrhythmia, left ventricular systolic dysfunction, and myocardial infarction.

205 (-/-) mice developed cardiac hypertrophy and systolic dysfunction, evidenced by a 5-fold greater hear

206 tion defects on the ECG and left ventricular systolic dysfunction.

207 e, atrial fibrillation, and left ventricular systolic dysfunction.

208 homeostasis in an efficient way to minimize systolic dysfunction.

209 ncrease in oxidative stress, hypertrophy and systolic dysfunction.

210 patients with concomitant moderate AS and LV systolic dysfunction.

211 years) complicated by left ventricular (LV) systolic dysfunction; (2) an age- and sex- matched hyper

212 The upper tail of the systolic (except boys) and diastolic BP distribution shi

213 g-axis function-lateral mitral annular plane systolic excursion (MAPSE)-in a large multicenter popula

214 diol levels (E2) and tricuspid annular plane systolic excursion (TAPSE) at 3 months.

215 ranscranial Doppler (vTCD) of straight sinus systolic flow velocity (FVsv), and methods derived from

216 s adjusted to the sarcomere length-dependent systolic force.

217 Abnormal LV structure, systolic function (based on LV ejection fraction and lon

218 mary outcome measures: left ventricular (LV) systolic function (left ventricular ejection fraction),

219 AAS users demonstrated relatively reduced LV systolic function (mean+/-SD left ventricular ejection f

220 nylephrine was inversely related to baseline systolic function (P < 0.05) and associated with markers

221 ndices to characterize left ventricular (LV) systolic function and its relationship to activation of

222 Systolic function in 32 patients with isolated moderate-

223 We aimed to study RV systolic function in patients with Chagas disease using

224 erload stress induces a deeper impairment of systolic function in patients with more advanced degrees

225 is the unexplained loss of maternal cardiac systolic function in the period surrounding parturition.

226 Omecamtiv mecarbil (OM) enhances systolic function in vivo by directly binding the myosin

227 LV systolic function is enhanced in cirrhosis due to augmen

228 infarct size and preserving left ventricular systolic function is primary percutaneous coronary inter

229 The ability to dynamically alter systolic function is significantly diminished, while the

230 s, 86+/-41 [46-195] g/m(2)) was progressive, systolic function mainly preserved (cardiac index 2.8+/-

231 lysis included 21 cohorts for structural and systolic function traits (n = 32,212) and 17 cohorts for

232 Systolic function was assessed by transthoracic echocard

233 cardiographic assessment of left ventricular systolic function were addressed at follow-up.

234 dimension, and RV and left ventricular (LV) systolic function were determined by RV fractional area

235 ificantly reduced infarct sizes and improved systolic function.

236 fibrosis and improvement of left ventricular systolic function.

237 ng at night ("sleep apnea") in patients with systolic heart failure (HF) have failed to improve progn

238 valuated and is used in select patients with systolic heart failure and chronic stable angina without

239 In patients with systolic heart failure not caused by ischemic heart dise

240 efibrillators] in Patients With Non-Ischemic Systolic Heart Failure on Mortality) did not demonstrate

241 prevention ICD in patients with nonischemic systolic heart failure warrants further investigation.

242 d to reduce hospitalization and mortality in systolic heart failure.

243 We studied patients with systolic HF (left ventricular ejection fraction </=45%)

244 In systolic HF patients, CAs occurred throughout a 24-h per

245 eeks in patients with recently decompensated systolic HF treated with anakinra, whereas an improvemen

246 city in patients with recently decompensated systolic HF.

247 w tract obstruction loss and right ventricle systolic impairment.

248 sympathetic prevalence on modulation of the systolic interval.

249 ation (N=58) showed significantly reduced LV systolic (left ventricular ejection fraction = 49+/-10%

250 Late systolic load has been shown to cause diastolic dysfunct

251 ings support the deleterious effects of late systolic loading on ventricular-atrial coupling.

252 Although the systolic loading sequence of the ventricular myocardium

253 therapy), blood pressure control (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting e

254 Measures of systolic LV function such as the ejection intraventricul

255 ts analysis was used to identify patterns of systolic motion that were most strongly predictive of su

256 MWS was associated with lower, whereas early systolic MWS was associated with greater LA function, in

257 independent correlates of LA function, late systolic MWS was associated with lower, whereas early sy

258 e integrals was computed as an index of late systolic myocardial load.

259 fication were observed in patients with late systolic or multiple jets (both kappa<0.2).

260 line infusion did not affect blood pressure, systolic, or diastolic left ventricular function.

261 essure (dp/dtmax ), and the slope of the end-systolic P-V relationship (ESPVR), suggesting that acute

262 me relationship during systole (Sslope); end-systolic peak (peak ); and diastolic uncoupling (systoli

263 1) and moderately correlated with the radial systolic peak strain (r = 0.478, p = 0.045).

264 ongitudinal motion (decreased mitral annular systolic peak velocities: control median, 0.11 m/s [inte

265 ular diameters compared with sizing based on systolic-phase multidetector computerized tomographic (M

266 Participants were exposed to intensive (goal systolic pressure < 120 mm Hg) versus standard (<140 mm

267 increased heart rate (HR), left ventricular systolic pressure (LVSP), the maximum first derivative o

268 able echocardiogram-derived pulmonary artery systolic pressure (PASP) from the Jackson Heart Study (N

269 n fraction) with PH (HF-PH; pulmonary artery systolic pressure [PASP] >/=40 mm Hg) were compared to n

270 ed modest increases in the right ventricular systolic pressure and right ventricle hypertrophy.

271 ity score of 3 or greater) and a prehospital systolic pressure between 40 and 119 mm Hg were included

272 d) were identified based on the RVESRI to RV systolic pressure relationship.

273 The slope of the end-systolic pressure volume relationship (i.e., contractili

274 horacic Surgeons score and right ventricular systolic pressure were 2+/-3 and 15+/-16 mm Hg, respecti

275 ces in age, country, hospital location, era, systolic pressure, mean arterial pressure, lactate, bund

276 A TR signals, echocardiographic measures of systolic pulmonary arterial pressure correlated reasonab

277 trial than left atrial enlargement and lower systolic pulmonary artery pressure compared with left-si

278 RV end-systolic remodeling index (RVESRI) was defined by latera

279 diastolic function at baseline and limiting systolic reserve under physiological stresses.

280 inal systolic strain and strain rate (SR) at systolic (SRs), early diastolic (SRe), and late diastoli

281 demonstrated higher peak atrial longitudinal systolic strain (39.34+/-7.99% versus 37.95+/-7.96%; P<0

282 ed with adverse cardiac remodeling and worse systolic strain and diastolic e' velocity.

283 Peak atrial longitudinal systolic strain and strain rate (SR) at systolic (SRs),

284 ent more pronounced peak atrial longitudinal systolic strain functional decay than those of men (P va

285 d the relationship between the ADC value and systolic strain in hypertensive patients with left ventr

286 tricular pressure difference (EIVPD) and the systolic strain rate were higher in patients with cirrho

287 RV systolic stretch fraction reflecting the ratio of myocar

288 nds assembled as a functional syncytium; (2) systolic twitch forces at a similar level as observed in

289 Point, non-angle-corrected peak systolic velocity (PSV) and resistive index (RI) values

290 d-diastolic volume (-18 mL; P=0.009) and end-systolic volume (-14 mL; P=0.005) occurred at end infusi

291 ght atrial volume than right ventricular end-systolic volume in AF-TR (P<0.001).

292 s of death (P < 0.01): right ventricular end-systolic volume index adjusted for age and sex, and the

293 anatomy, and left ventricular function, end-systolic volume index and B-type natriuretic peptide wer

294 f left ventricular ejection fraction and end-systolic volume, but not with the severity of brain or b

295 ration in LV end-diastolic volume and LV end-systolic volume.

296 t reduction of left ventricular volumes (end-systolic volume: -4.3 [11.3] versus 7.4 [11.8], P=0.02;

297 indexed RV end-diastolic volumes and RV end-systolic volumes (RVESVi) (indexed RV end-diastolic volu

298 ry were associated primarily with changes in systolic volumes, longitudinal and circumferential strai

299 eased in both groups (P < 0.001), as was end-systolic wall stress (P < 0.001).

300 ess (hypertrophy) and function (diastolic or systolic), which lack mechanistic specificity, paradigms